Sclerosis News and Research

RSS

EMD Serono, Brigham and Women's Hospital collaborate in MS research

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced a strategic collaboration with Brigham and Women's Hospital in Boston, to advance basic and clinical research in multiple sclerosis (MS), with the goal of generating new and innovative discoveries that advance treatment for people living with this condition. The multi-faceted agreement will run for up to 5 years, with the potential to renew the alliance thereafter. Both parties decided not to disclose financial details.

16 Dec 2009

Study suggests physical activity influences depression and fatigue by increasing self-efficacy

Physical activity is known to reduce depression and fatigue in people struggling with chronic illness. A new study indicates that this effect stems from an individual's sense of mastery over - or belief in his or her ability to achieve - certain physical goals.

16 Dec 2009

ALS TDI and Applied Proteomics join to identify protein biomarkers associated with ALS

The ALS Therapy Development Institute (ALS TDI) and Applied Proteomics, Inc. announced today that they have completed the first stage of a multi-year collaboration to identify and validate protein biomarkers associated with amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease).

15 Dec 2009

UT researchers identify new molecule that slows ALS progression in mice

Researchers at UT Southwestern Medical Center have found that a molecule produced naturally by muscles in response to nerve damage can reduce symptoms and prolong life in a mouse model of amyotrophic lateral sclerosis (ALS).

11 Dec 2009

microRNA-206 plays crucial role in the progression of ALS

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, today announced the publication of data demonstrating that microRNA-206 (miR-206) plays a crucial role in the progression of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and in neuromuscular synaptic regeneration in mice.

11 Dec 2009

Prize4life partners with Jackson Laboratory on AML research

Prize4Life, an organization dedicated to finding a cure for amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease), is partnering with The Jackson Laboratory to help more researchers identify treatment candidates that increase the lifespan of mice that model ALS.

11 Dec 2009

JMC receives NIH grant to establish center of excellence for autoimmune diseases

The Department of Neurology at Jefferson Medical College (JMC) of Thomas Jefferson University has been awarded a multi-million dollar grant from the National Institutes of Health (NIH) for the creation of a center of excellence to study autoimmune diseases from basic science research to its translation into clinical applications.

10 Dec 2009

Additional data from ALS patients enrolled in confirmatory Phase III STAR trial announced

AVANIR Pharmaceuticals, Inc. today announced additional data from the subset of patients with amyotrophic lateral sclerosis (ALS) enrolled in the confirmatory Phase III STAR trial.

9 Dec 2009

Preliminary data from Phase 2 clinical trial of ZFP Therapeutic program presented

Sangamo BioSciences, Inc. announced today the presentation of preliminary data from the Phase 2 clinical trial of its ZFP Therapeutic(TM) program to develop SB-509 as a treatment for amyotrophic lateral sclerosis (ALS) at a Work in Progress session at the 20th International Symposium on ALS/MND held in Berlin, Germany.

9 Dec 2009

Clinical results from Phase 2 study of KNS-760704 presented by Knopp Neurosciences

Knopp Neurosciences Inc. (“Knopp”) announced the presentation today of encouraging clinical results in a Phase 2 safety and tolerability study of KNS-760704 in amyotrophic lateral sclerosis (“ALS”).

9 Dec 2009

Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study

Genzyme Corporation announced today that a Phase 1/2 trial provided early clinical data suggesting that Mozobil (plerixafor injection) in combination with chemotherapy may offer a therapeutic impact on leukemic cells protected in bone marrow.

9 Dec 2009

Cedars-Sinai Regenerative Medicine Institute supplies stem cells to aid Huntington's disease research

The Cedars-Sinai Regenerative Medicine Institute is to provide stem cells to a five-member National Institutes of Health consortium of researchers for development of potential therapies to treat Huntington's disease.

8 Dec 2009

Biogen Idec's BG-12 achieves key milestones in clinical trials for MS and RA

Biogen Idec today announced that its oral compound BG-12 (dimethyl fumarate) achieved key milestones in clinical trials for multiple sclerosis (MS) and rheumatoid arthritis (RA).

8 Dec 2009

Stem cell treatment: A new hope for Multiple Sclerosis

RNL Bio Co., Ltd, (www.rnl.co.kr) a leading biopharmaceutical company specialized in adult stem cell therapeutics announced today that a 46-year-old female, Kang Sook Park's Multiple Sclerosis improved tremendously after receiving stem cell treatment. Park was suffering from MS (Multiple Sclerosis), an autoimmune disease that affects the central nervous system (brain and spinal cord).

6 Dec 2009

Biogen Idec increases its offer to $17.50 for purchase of Facet Biotech shares

Biogen Idec Inc. today announced that it has increased its offer to purchase all of the outstanding shares of Facet Biotech Corporation to $17.50 per share in cash, representing an increase of $3.00 per share, or 21%, over its previous offer.

4 Dec 2009

Cannabis can reduce spasticity in MS patients

Cannabis can reduce spasticity in multiple sclerosis (MS) patients. A systematic review, published in the open access journal BMC Neurology, found that five out six randomized controlled trials reported a reduction in spasticity and an improvement in mobility.

4 Dec 2009

FDA approves revised clinical trial protocol for CytRx' arimoclomol

CytRx Corporation, a biopharmaceutical company, is permitted to re-enter the clinic with its orally administered molecular chaperone drug candidate arimoclomol as a therapeutic treatment for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), following the U.S. Food and Drug Administration’s (FDA) acceptance of a revised clinical trial protocol.

2 Dec 2009

New approach to identify molecules that prevent immune cells from attacking body

A study led by a Scripps Research Institute scientist describes a new, highly pragmatic approach to the identification of molecules that prevent a specific type of immune cells from attacking their host. The findings add a powerful new tool to the ongoing search for potential treatments for autoimmune diseases, such as multiple sclerosis (MS), as well as blood cancers, such as myeloid leukemia.

2 Dec 2009

Article on TYSABRI for treating patients with multiple sclerosis published

Best-practice recommendations for the selection and management of patients with multiple sclerosis (MS) who may benefit from, or are receiving treatment with TYSABRI- (natalizumab) were published today in a supplement to the medical journal Multiple Sclerosis.

1 Dec 2009

Research shows link between nervous and immune systems; findings may lead to new treatments for autoimmune disorders

New research in the Journal of Leukocyte Biology shows the link between the nervous and immune systems and how breaking that link might lead to new treatments for a wide range of autoimmune disorders

1 Dec 2009

Sclerosis News and Research

EMD Serono, Brigham and Women's Hospital collaborate in MS research

Study suggests physical activity influences depression and fatigue by increasing self-efficacy

ALS TDI and Applied Proteomics join to identify protein biomarkers associated with ALS

UT researchers identify new molecule that slows ALS progression in mice

microRNA-206 plays crucial role in the progression of ALS

Prize4life partners with Jackson Laboratory on AML research

JMC receives NIH grant to establish center of excellence for autoimmune diseases

Additional data from ALS patients enrolled in confirmatory Phase III STAR trial announced

Preliminary data from Phase 2 clinical trial of ZFP Therapeutic program presented

Clinical results from Phase 2 study of KNS-760704 presented by Knopp Neurosciences

Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study

Cedars-Sinai Regenerative Medicine Institute supplies stem cells to aid Huntington's disease research

Biogen Idec's BG-12 achieves key milestones in clinical trials for MS and RA

Stem cell treatment: A new hope for Multiple Sclerosis

Biogen Idec increases its offer to $17.50 for purchase of Facet Biotech shares

Cannabis can reduce spasticity in MS patients

FDA approves revised clinical trial protocol for CytRx' arimoclomol

New approach to identify molecules that prevent immune cells from attacking body

Article on TYSABRI for treating patients with multiple sclerosis published

Research shows link between nervous and immune systems; findings may lead to new treatments for autoimmune disorders

Industry Focus eBook - Cell biology (5th edition) eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News